Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Saved in:
| Title: | Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. |
|---|---|
| Authors: | Campbell KM; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: katiecampbell@mednet.ucla.edu., Amouzgar M; Department of Pathology, Stanford University, Stanford, CA 94305, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Pfeiffer SM; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Howes TR; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Medina E; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Travers M; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Steiner G; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Weber JS; Perlmutter Cancer Center, NYU School of Medicine, New York, NY 10016, USA., Wolchok JD; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York, NY 10065, USA., Larkin J; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Boffo S; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA., Salvador L; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA., Tenney D; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA., Tang T; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA., Thompson MA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Spencer CN; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Wells DK; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA., Ribas A; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90024, USA. Electronic address: aribas@mednet.ucla.edu. |
| Source: | Cancer cell [Cancer Cell] 2023 Apr 10; Vol. 41 (4), pp. 791-806.e4. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
